Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia
In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.
2002 ◽
Vol 30
(10)
◽
pp. 1124-1131
◽
2009 ◽
Vol 32
(1)
◽
pp. 79-85
◽
1996 ◽
Vol 184
(4)
◽
pp. 1377-1384
◽
1987 ◽
Vol 130
(2)
◽
pp. 255-261
◽
1998 ◽
Vol 34
(12)
◽
pp. 1958-1961
◽